Objective To study the expression and clinical significance of topoisomerse Ⅱα (TOPO Ⅱ α) and urokinase type plasmivnogen activator (UPA) in breast cancer. Methods The expressions of TOPO Ⅱα and UPA were examined with streptavidin-perosidase immunohistochemistry method in 69 cases of breast cancer. Results The positive rates of TOPO Ⅱα and UPA were 42.03% (29/69) and 59.42% (41/69) in breast cancer respectively. TOPO Ⅱα had a high relation with UPA in breast cancer (r = 0.9984). The positive rates of TOPO Ⅱα in non-lymph metastasis group was higher than that in lymph metastasis (P < 0.05). The positive rates of UPA in non-lymph metastasis group was higher than that in lymph metastasis too (P < 0.05), but its pathological type and breast cancer pathological type relevance was not obvious (P > 0.05). Conclusion The expression of TOPO Ⅱα and UPA have relation with breast cancer metastasis. It is directing significance of detection of TOPO Ⅱα and UPA on clinical selection treatment.%目的 研究乳腺癌组织中拓扑异构酶Ⅱα(TOPOⅡα)和尿激酶型纤溶酶原激活物(UPA)表达的相关性及临床意义.方法 采用免疫组织化学SP法,检测69例乳腺癌组织中TOPOⅡα及UPA的表达情况.结果 乳腺癌中TOPOⅡα的阳性率为42.03%(29/69),UPA的阳性率为59.42%(41/69),二者的表达成高度正相关(r = 0.9984).TOPOⅡα在无淋巴结转移组的阳性表达率明显高于有淋巴结转移组(P < 0.05),UPA在无淋巴结转移组的阳性表达率也明显高于有淋巴结转移组(P < 0.05),二者与乳腺癌的年龄、部位无明显相关性.结论 TOPOⅡα和UPA在乳腺癌中表达与淋巴结转移有相关性.检测TOPOⅡα和UPA对临床选择治疗方法有指导意义.
展开▼
